DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
LY3154207 is an investigational drug.
There have been 7 clinical trials for LY3154207. The most recent clinical trial was a Phase 1 trial, which was initiated on November 10th 2017.
The most common disease conditions in clinical trials are Parkinson Disease, Dementia, and [disabled in preview]. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].
There is one US patent protecting this investigational drug and forty-six international patents.
Recent Clinical Trials for LY3154207
|A Study to Evaluate LY3154207 on the Brain of Healthy Participants||Eli Lilly and Company||Phase 1|
|A Drug Interaction Study of LY3154207 in Healthy Participants||Eli Lilly and Company||Phase 1|
|Study of LY3154207 in Healthy Participants||Eli Lilly and Company||Phase 1|
Top disease conditions for LY3154207
Top clinical trial sponsors for LY3154207
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|LY3154207||Start Trial||3,4-dihydroisoquinolin-2(1H)-yl compounds||Eli Lilly and Company (Indianapolis, IN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|